IDO immune status after chemoradiation may predict survival in lung cancer patients

Weili Wang, Lei Huang, Jian Yue Jin, Shruti Jolly, Yong Zang, Huanmei Wu, Li Yan, Wenhu Pi, Lang Li, Andrew L. Mellor, Feng Ming Kong

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non–small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during, and after RT administration and then correlated to overall survival (OS), progression-free survival, and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months of median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival. Significance: Radiotherapy appears to influence systemic IDO activity and to exert a significant impact on metastatic risk and overall survival, with possible implications for defining a biomarker to optimize radiation dose in patients to improve outcomes.

Original languageEnglish (US)
Pages (from-to)809-816
Number of pages8
JournalCancer Research
Volume78
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Lung Neoplasms
Radiotherapy
Kynurenine
Survival
Non-Small Cell Lung Carcinoma
Tryptophan
Radiotherapy Dosage
Biomarkers
Serum
Disease-Free Survival
Disease Progression
Immunity
Radiation
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wang, W., Huang, L., Jin, J. Y., Jolly, S., Zang, Y., Wu, H., ... Kong, F. M. (2018). IDO immune status after chemoradiation may predict survival in lung cancer patients. Cancer Research, 78(3), 809-816. https://doi.org/10.1158/0008-5472.CAN-17-2995

IDO immune status after chemoradiation may predict survival in lung cancer patients. / Wang, Weili; Huang, Lei; Jin, Jian Yue; Jolly, Shruti; Zang, Yong; Wu, Huanmei; Yan, Li; Pi, Wenhu; Li, Lang; Mellor, Andrew L.; Kong, Feng Ming.

In: Cancer Research, Vol. 78, No. 3, 01.02.2018, p. 809-816.

Research output: Contribution to journalArticle

Wang, W, Huang, L, Jin, JY, Jolly, S, Zang, Y, Wu, H, Yan, L, Pi, W, Li, L, Mellor, AL & Kong, FM 2018, 'IDO immune status after chemoradiation may predict survival in lung cancer patients', Cancer Research, vol. 78, no. 3, pp. 809-816. https://doi.org/10.1158/0008-5472.CAN-17-2995
Wang, Weili ; Huang, Lei ; Jin, Jian Yue ; Jolly, Shruti ; Zang, Yong ; Wu, Huanmei ; Yan, Li ; Pi, Wenhu ; Li, Lang ; Mellor, Andrew L. ; Kong, Feng Ming. / IDO immune status after chemoradiation may predict survival in lung cancer patients. In: Cancer Research. 2018 ; Vol. 78, No. 3. pp. 809-816.
@article{5d81c59f403542b9827ac0f50303bf2e,
title = "IDO immune status after chemoradiation may predict survival in lung cancer patients",
abstract = "Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non–small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during, and after RT administration and then correlated to overall survival (OS), progression-free survival, and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months of median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival. Significance: Radiotherapy appears to influence systemic IDO activity and to exert a significant impact on metastatic risk and overall survival, with possible implications for defining a biomarker to optimize radiation dose in patients to improve outcomes.",
author = "Weili Wang and Lei Huang and Jin, {Jian Yue} and Shruti Jolly and Yong Zang and Huanmei Wu and Li Yan and Wenhu Pi and Lang Li and Mellor, {Andrew L.} and Kong, {Feng Ming}",
year = "2018",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-17-2995",
language = "English (US)",
volume = "78",
pages = "809--816",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - IDO immune status after chemoradiation may predict survival in lung cancer patients

AU - Wang, Weili

AU - Huang, Lei

AU - Jin, Jian Yue

AU - Jolly, Shruti

AU - Zang, Yong

AU - Wu, Huanmei

AU - Yan, Li

AU - Pi, Wenhu

AU - Li, Lang

AU - Mellor, Andrew L.

AU - Kong, Feng Ming

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non–small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during, and after RT administration and then correlated to overall survival (OS), progression-free survival, and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months of median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival. Significance: Radiotherapy appears to influence systemic IDO activity and to exert a significant impact on metastatic risk and overall survival, with possible implications for defining a biomarker to optimize radiation dose in patients to improve outcomes.

AB - Host immunity influences the impact of radiotherapy (RT) in cancer, but mechanistic connections remain obscure. In this study, we investigated the relationship of indoleamine 2,3-dioxygenase (IDO) systemic activity on clinical outcomes in RT-treated non–small cell lung cancer (NSCLC). IDO-mediated production of kynurenine and the kynurenine:tryptophan ratio in patient blood serum were determined for stage III NSCLC patients at times before, during, and after RT administration and then correlated to overall survival (OS), progression-free survival, and disease progression rate in patients. We found the impact of RT on these serum IDO markers to be heterogeneous in patients. On average, kynurenine:tryptophan ratios were reduced during RT but restored after RT. Notably, both baseline levels of kynurenine:tryptophan and changes in the levels of kynurenine after RT were significantly associated with OS. When combined, favorable change and favorable baseline corresponded with very long-term OS (median OS was not reached after 57 months of median follow-up). Favorable change combined with unfavorable baseline still corresponded with a lack of distant metastases. Our results suggest that RT alters IDO-mediated immune status in NSCLC patients and that changes in this serum biomarker may be useful to predict outcomes and perhaps personalize RT dosage to improve survival. Significance: Radiotherapy appears to influence systemic IDO activity and to exert a significant impact on metastatic risk and overall survival, with possible implications for defining a biomarker to optimize radiation dose in patients to improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85041475702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041475702&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-2995

DO - 10.1158/0008-5472.CAN-17-2995

M3 - Article

AN - SCOPUS:85041475702

VL - 78

SP - 809

EP - 816

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -